Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: Effect on hormonal levels and follicular development

Human Reproduction

Volumn 22, Issue 6, 2007, Pages 1540-1546

  Lainas, Trifon G ^a   Petsas, George K ^a   Zorzovilis, Ioannis Z ^a   Iliadis, George S ^a   Lainas, George T ^a   Cazlaris, Haris E ^b   Kolibianakis, Efstratios M ^c  

^a Eugonia Iatriki Erevna IVF Centre   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Antagonist luteinizing hormone; Estradiol; Follicular development; GnRH agonist; PCOS

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HORMONE; LONG ACTING DRUG; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 34447318868     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem033     Document Type: Article

References (25)

1. Al-Inany H and Aboulghar M (2002) GnRH antagonist in assisted reproduction: A Cochrane review. Hum Reprod 17,874-885.
2. Al-Inany H, Aboulghar M, Mansour R and Serour G (2005) Optimizing GnRH antagonist administration: Meta-analysis of fixed versus flexible protocol. RBM Online 10,567-570.
3. Bahceci M, Ulug U, Ben-Shlomo I, Erden HF and Akman MA (2005) Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: A randomized, prospective, pilot study. J Reprod Med 50,84-90.
4. Barash A, Weissman A, Mamor M, Milman D, Ben-Arie A and Shoham Z (1998) Prospective evaluation of endometrial thickness as a predictor of pituitary down regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program. Fertil Steril 69,496-499.
5. Brinsden PR, Wada I, Tan SL, Balen A and Jacobs HS (1995) Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 102,767-772.
6. Devroey P and Van Steirteghem A (2004) A review of ten years experience of ICSI. Hum Reprod Update 10,19-28.
7. Ehrmann A, Barnes R and Rosenfield R (2006) Hyperandrogenism, hirsutism, and the polycystic ovary syundrome. In Degroot L and Jameson J (eds) Endocrinology. Elsevier, Philadelphia, USA, 2790.
8. Elkind-Hirsch KE, Webster BW, Brown CP and Vernon MW (2003) Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79,603-607.
9. Fauser BC and Devroey P (2005) Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 83,1607-1611.
10. Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, Parmegiani L, Pelusi G and De Aloysio D (2002) The use of LH activity to drive folliculogenesis: Exploring uncharted territories in ovulation induction. Hum Reprod Update 8,543-557.
11. Griesinger G, Felberbaum R and Diedrich K (2005) GnRH antagonists in ovarian stimulation: A treatment regimen of clinicians' second choice? Data from the German national IVF registry. Hum Reprod 20,2373-2375.
12. Hwang JL, Scow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH, et al. (2004) Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: A prospective randomized study. Hum Reprod 19,1993-2000.
13. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003a) Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: Effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 88,5632-5637.
14. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003b) Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 79,873-880.
15. Kolibianakis E, Albano C, Zikopoulos K, Kahn JA, Van Steirteghem A and Devroey P (2004) GnRH antagonists in poor responders. Acta Obstet Gynecol Scand 83,1216-1217.
16. Kolibianakis EM, Tarlatzis B and Devroey P (2005) GnRH antagonists in IVF. Reprod Biomed Online 10,705-712.
17. Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V, Lainas G and Alexopoulou E (2005) In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod 20,2426-2433.
18. Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, Drakakis P, Dafopoulos K and Milingos S (2005) Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Hum Reprod 20,3192-3197.
19. Navot D, Bergh PA and Laufer N (1992) Ovarian hyperstimulation on syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 58,249-261.
20. Rizk B and Aboulghar MA (1993) Classification, pathophysiology and management of ovarian hyperstimulation syndrome. Brinsden P (ed.) In Vitro Fertilization and Assisted Reproduction. The Parthenon Publishing Group, New York, London, pp. 131-155.
21. The ganirelix dose-finding study group (1998) A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13,3023-3031.
22. van der Westerlaken L, Naaktgeboren N, Verburg H, Dieben S and Helmerhorst FM (2006) Conventional in vitro fertilization versus intracytoplasmic sperm injection in patients with borderline semen: A randomized study using sibling oocytes. Fertil Steril 85,395-400.
23. Van Landuyt L, De Vos A, Joris H, Verheyen G, Devroey P and Van Steirteghem A (2005) Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: Influence of the fertilization procedure. Fertil Steril 83,1397-1403.
24. Vicdan K and Isik AZ (1999) Intracytoplasmic sperm injection is not associated with poor outcome in couples with normal semen parameters and previous idiopathic fertilization failure in conventional in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 87,87-90.
25. WHO (1999) Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction, 4th edn. Cambridge University Press, Cambridge.